China-based Haisco Pharmaceutical has granted Sentivera Therapeutics, a US biotech backed by Population Health Partners and ARCH Venture Partners with USD 83 million committed capital, exclusive ex-Greater China rights to a proprietary oral small-molecule anti-inflammatory asset, in a deal worth USD 75.89 million upfront (USD 40 million cash plus 17.5% Sentivera equity, 11,964,016 shares) and up to USD 1.46 billion in development, regulatory, and commercial milestones, plus tiered royalties up to 10% of net sales and sublicensing revenue share.

Haisco retains Greater China rights to the molecule, which has cleared China IND approval and shown clear mechanism and significant efficacy in preclinical autoimmune models, though no Phase I data have been disclosed.